Blake Borgeson - 03 Nov 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

SEC form
4
Accepted by SEC
04 Nov 2026, 17:12:32 UTC
Prior SEC filing
07 Oct 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Blake Borgeson filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 04 Nov 2026.

Key facts

  • This page summarizes Blake Borgeson's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 04 Nov 2026, 17:12.

Change

  • Previous filing in this sequence was filed on 07 Oct 2026.
  • Current net transaction value: -$155,200.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001856094 Primary reporting owner

Borgeson Blake

Relationship
Director

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Sale

Transaction value
-$155,200
Shares
-40,000
Change %
-0.65%
Price
$3.88
Shares after
6,068,287
Date
03 Nov 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $3.84 to $4.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .